Abstract:Background: Stereotactic radiosurgery (SRS) is considered a promising treatment for brain metastases (BM) with better healing efficacy, relatively faster treatment time, and lower neurotoxicity, which can achieve local control rates above 70%. Although SRS improves the local control of BM, this may not translate into improvements in survival time. Thus, screening out the key factors influencing the treatment response to SRS, instead of the survival time following SRS, might be of more significance. This may assist doctors when making adjustments to treatment strategies for patients with BM. Methods: This is a retrospective review of 696 patients with BM who were treated with SRS at Huashan Hospital, Fudan University between June 2015 and February 2020. According to the patients’ treatment response to SRS, the patients were divided into an improved group (IG) and a progressive group (PG). The clinical data and magnetic resonance imaging (MRI) performed pre- and post-treatment were collected for the two groups. Five clinical variables (gender, age, Karnofsky performance status (KPS), primary tumor type, and extracranial lesion control) and seven radiological manifestations (location, number, volume, maximum diameter, edema index (EI), diffusion weighted imaging (DWI) sequence signal, and enhanced pattern) were selected and compared. A stepwise regression analysis was performed in order to obtain the best prediction effect of a group of variables and their regression coefficients, and finally to build an SRS treatment response scoring model based on the coefficients. The performance of the model was evaluated by calculating the AUC and performing the Hosmer–Lemeshow test. Results: A total of 323 patients were enrolled in the study based on the inclusion and exclusion criteria, including 209 patients in the IG and 114 patients in the PG. In the Chi-square test and t-test analysis, the significant p values of KPS, extracranial lesion control, volume, and EI were less than 0.05. Moreover, the cut-off values for volume and EI were 1801.145 mm3 and 3.835, respectively. The scoring model that was based on multivariate logistic regression coefficients performed better, achieving AUCs of 0.755 ± 0.062 and 0.780 ± 0.061 for the internal validation and validation cohorts, with p values of 0.168 and 0.073 for the Hosmer–Lemeshow test. Conclusions: KPS, extracranial lesion control, tumor volume, and EI had a certain correlation with the treatment response to SRS. Scoring models that are based on these variables can accurately predict the treatment response of patients with BM to SRS, thereby assisting doctors to make an appropriate first treatment strategy for patients with BM to a certain degree.

Comprehensive Analysis of Blood Test Results Predicting Prognosis in Patients Undergoing Whole-brain Radiotherapy for Brain Metastases

Neutrophil-lymphocyte Ratio As a Prognostic Factor for Stereotactic Body Radiotherapy Treatment of Metastatic Liver Tumors.

Whole Brain Radiotherapy-Based Combined Modality Treatment of Brain Metastases from Non-Small Cell Lung Cancer: A Retrospective Analysis of Prognostic Factors

Analysis of prognostic factors and index model in patients with brain metastases after whole-brain radiotherapy

Predicting Survival with Brain Metastases in the Stereotactic Radiosurgery Era: are Existing Prognostic Scores Still Relevant? Or Can we do Better?

Added survival benefit of whole brain radiotherapy in brain metastatic non-small cell lung cancer: Development and external validation of an individual prediction model

Prognostic Analysis of Stereotactic Radiosurgery for Brain Metastases: a Single-Center Retrospective Study

Postoperative treatment and prognosis of patients with resected single brain metastasis: How useful are established prognostic scores?

The Incidence and Prognosis of Brain Metastasis after Radical Chemoradiotherapy in Non-Small Cell Lung Cancer

The Analysis of Effect about Different Therapies on Brain Metastases from Non-Small Cell Lung Cancer

Pretreatment lymphocyte-to-monocyte ratio as a prognostic factor and influence on dose-effect in fractionated stereotactic radiotherapy for oligometastatic brain metastases in non-small cell lung cancer patients

Prognostic predictors for breast cancer patients with brain metastasis after radiotherapy

Prognostic significance of lab data and performance comparison by validating survival prediction models for patients with spinal metastases after radiotherapy

Individualized Nomogram for Predicting Survival in Patients with Brain Metastases After Stereotactic Radiosurgery Utilizing Driver Gene Mutations and Volumetric Surrogates

Analysis of prognostic factors and prognostic indices in breast cancer patients with brain metastases after whole-brain radiotherapy

Prognostic Factors and Impact of Therapeutic Intervention in Patients With Brain Metastases at the Initial Presentation

Prognostic value of pre-treatment neutrophil-to-lymphocyte ratio in patients with brain metastasis from cancer: a meta-analysis

Effects of Whole-Brain Radiation Therapy and Other Factors on Survival in Patients with Brain Metastases from Lung Cancer

External Validity of a Risk Stratification Score Predicting Early Distant Brain Failure and Salvage Whole Brain Radiation Therapy After Stereotactic Radiosurgery for Brain Metastases

Analysis of Key Clinical Variables and Radiological Manifestations Associated with the Treatment Response of Patients with Brain Metastases to Stereotactic Radiosurgery

Lymphopenia associated with whole-brain radiotherapy and its effects on clinical outcomes of patients with brain metastases